Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1145-1153

  Heiblig, M ^a   Sobh, M ^a   Nicolini, F E ^a,b,c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c French Group of CML (Fi LMC Group)   (France)

Author keywords

BCR ABL mutation; Chronic phase CML; Imatinib; Imatinib resistance; T315I

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; CYTARABINE; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; DRUG TOLERANCE; GENE MUTATION; HUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SURVIVAL RATE; ANIMAL; BCR-ABL MUTATION; CHRONIC PHASE CML; DRUG EFFECT; DRUG RESISTANCE; IMATINIB RESISTANCE; SUBCUTANEOUS DRUG ADMINISTRATION; T315I;

BCR-ABL MUTATION; CHRONIC PHASE CML; IMATINIB; IMATINIB RESISTANCE; T315I;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; HARRINGTONINES; HUMANS; INFUSIONS, SUBCUTANEOUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 84908021723     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.05.007     Document Type: Review

References (82)

1. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
2. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
3. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
4. Deininger M. Resistance and relapse with imatinib in CML: causes and consequences. J Natl Comprehen Cancer Network: JNCCN 2008, 6(Suppl 2):S11-S21.
5. Nicolini F.E., Ibrahim A.R., Soverini S., Martinelli G., Muller M.C., Hochhaus A., et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 2013, 98:1510-1516.
6. Hamilton A., Helgason G.V., Schemionek M., Zhang B., Myssina S., Allan E.K., et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012, 119:1501-1510.
7. de Lavallade H., Khorashad J.S., Davis H.P., Milojkovic D., Kaeda J.S., Goldman J.M., et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007, 110:2779-2780.
8. Nicolini F.E., Lipton J.H., Kantarjian H., Wetzler M., Akard L.P., Baccarani M., et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). J. Clin. Oncol. 2012, 30. (suppl; abstr 6513).
9. Kantarjian H.M., Talpaz M., Santini V., Murgo A., Cheson B., O'Brien S.M. Homoharringtonine: history, current research, and future direction. Cancer 2001, 92:1591-1605.
10. Huang C.C., Han C.S., Yue X.F., Shen C.M., Wang S.W., Wu F.G., et al. Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J Natl Cancer Inst 1983, 71:841-847.
11. Group CRC Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 1976, 2:263-272.
12. Powell R.G., Weisleder D., Smith C.R., Rohwedder W.K. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970, 815-818.
13. Powell R., Weislerder D., Smith C.R. Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J Pharm Sci 1972, 61:1227-1230.
14. Baaske D.M., Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977, 12:298-300.
15. Takemura Y., Ohnuma T., Chou T.C., Okano T., Holland J.F. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985, 14:206-210.
16. Fresno M., Jimenez A., Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Euro J Biochem/FEBS 1977, 72:323-330.
17. Department of Pharmacology IoMM The antitumor effects and pharmacologic actions of harringtonine. Chin Med J 1977, 3:131-136.
18. Zhou J.Y., Chen D.L., Shen Z.S., Koeffler H.P. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990, 50:2031-2035.
19. Tang R., Faussat A.M., Majdak P., Marzac C., Dubrulle S., Marjanovic Z., et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Thera 2006, 5:723-731.
20. Allan E.K., Holyoake T.L., Craig A.R., Jorgensen H.G. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011, 25:985-994.
21. Krutzik P.O., Crane J.M., Clutter M.R., Nolan G.P. High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol 2008, 4:132-142.
22. Chen Y., Hu Y., Michaels S., Segal D., Brown D., Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009, 23:1446-1454.
23. Chen R., Guo L., Chen Y., Jiang Y., Wierda W.G., Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011, 117:156-164.
24. Klag T., Hartel N., Erben P., Schwaab J., Schnetzke U., Schenk T., et al. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common beta-subunit c of cytokine receptors. Leukemia 2012, 26:1321-1328.
25. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
26. Kuroda J., Kamitsuji Y., Kimura S., Ashihara E., Kawata E., Nakagawa Y., et al. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 2008, 87:507-515.
27. Wetzler M., Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharma Des 2011, 17:59-64.
28. Kulkarni H., Goring H.H., Diego V., Cole S., Walder K.R., Collier G.R., et al. Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines. BMC Med Genomics 2012, 5:37.
29. Legha S.S., Keating M., Picket S., Ajani J.A., Ewer M., Bodey G.P. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984, 68:1085-1091.
30. Quintas-Cardama A., Kantarjian H., Garcia-Manero G., O'Brien S., Faderl S., Estrov Z., et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, 109:248-255.
31. Burton C., Ranger A., Nadal E. Semi-synthetic homoharringtonine (MyelostatVR) for chronic myeloid leukemia in accelerated phase after imatinib failure. Blood 2003, 102. [abstract].
32. Maloisel F., Rousselot P., Morariu R. Subcutaneous hemi-synthetic homoharringtonine (HHT) in combination with imatinib mesylate (Gleevec) in patients (PTS) with STI-resistant chronic myelogenous leukemia (CML): preliminary results of a pilot study. Blood (Annu Meet Abs) 2003, 102. [abstract].
33. O'Brien S., Kantarjian H., Keating M., Beran M., Koller C., Robertson L.E., et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995, 86:3322-3326.
34. Nanda N., Cortes C., Lipton J., Rea D., Digumarti R., Chuah C., et al. Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data. Haematologica 2011, 96:422-423.
35. Cortes-Franco J., Raghunadharao D., Parikh P., Wetzler M., Lipton J., Jones D., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors-results of a multicenter phase 2/3 study. Blood (Annu Meet Abs) 2009, 114. [abstract].
36. Nemunaitis J., Mita A., Stephenson J., Mita M.M., Sarantopoulos J., Padmanabhan-Iyer S., et al. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol 2013, 71:35-41.
37. Savaraj N., Lu K., Dimery I., Feun L.G., Burgess M., Keating M., et al. Clinical pharmacology of homoharringtonine. Cancer Treat Rep 1986, 70:1403-1407.
38. Cui Y.Y., Wang M.Z. The metabolism of homoharringtonine by liver microsomes of rats and rabbits. Yao xue xue bao=Acta Pharma Sinica 1991, 26:274-279.
39. Savaraj N., Feun L.G., Lu K., Leavens M., Moser R., Fields W.S., et al. Central nervous system (CNS) penetration of homoharringtonine (HHT). J Neuro-oncol 1987, 5:77-81.
40. Jin J., Wang J.X., Chen F.F., Wu D.P., Hu J., Zhou J.F., et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013, 14:599-608.
41. Pei R.Z., Li S.Y., Zhang P.S., Ma J.X., Liu X.H., Du X.H., et al. Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia. Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi 2013, 34:144-148.
42. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol/Educ Programe Am Soc Hematol Am Soc Hematol Educ Program 2009, 461-476.
43. Willis S.G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
44. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100:3041-3044.
45. Ernst T., Erben P., Muller M.C., Paschka P., Schenk T., Hoffmann J., et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008, 93:186-192.
46. Khorashad J.S., Kelley T.W., Szankasi P., Mason C.C., Soverini S., Adrian L.T., et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013, 121:489-498.
47. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
48. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
49. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
50. Nicolini F.E., Corm S., Le Q.H., Sorel N., Hayette S., Bories D., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006, 20:1061-1066.
51. Nicolini F.E., Hayette S., Corm S., Bachy E., Bories D., Tulliez M., et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007, 92:1238-1241.
52. Nicolini F.E., Mauro M.J., Martinelli G., Kim D.W., Soverini S., Muller M.C., et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009, 114:5271-5278.
53. Lange T., Ernst T., Gruber F.X., Maier J., Cross M., Muller M.C., et al. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 2013, 98:714-717.
54. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
55. Talpaz M., Hehlmann R., Quintas-Cardama A., Mercer J., Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2013, 27:803-812.
56. Itonaga H., Tsushima H., Hata T., Matsuo E., Imanishi D., Imaizumi Y., et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 2012, 95:209-213.
57. Ilander M., Koskenvesa P., Hernesniemi S., Lion T., Porkka K., Mustjoki S. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy. Leuk. Lymphoma 2014, 55:934-937.
58. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., Biggs W.H., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006, 66:1007-1014.
59. Giles F.J., Swords R.T., Nagler A., Hochhaus A., Ottmann O.G., Rizzieri D.A., et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013, 27:113-117.
60. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
61. Cortes J., Kim D., Pinella-Ibarz J. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
62. Speck B., Bortin M.M., Champlin R., Goldman J.M., Herzig R.H., McGlave P.B., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984, 1:665-668.
63. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol: Off J Am Soc Clin Oncol 2009, 27:6041-6051.
64. Jabbour E., Cortes J., Kantarjian H.M., Giralt S., Jones D., Jones R., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006, 108:1421-1423.
65. Nicolini F.E., Zhou W., Martinelli G. Impact of allogeneic stem cell transplantation as salvage therapy after T315I mutation detection in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients. Blood (Ann Meet Abs) 2009, 114.
66. Nicolini F.E., Basak G.W., Soverini S., Martinelli G., Mauro M.J., Muller M.C., et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011, 118:5697-5700.
67. Witte R.S., Hsieh P., Elson P., Oken M.M., Trump D.L. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest N Drugs 1996, 14:409-413.
68. Witte R.S., Lipsitz S., Goodman T.L., Asbury R.F., Wilding G., Strnad C.M., et al. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest N Drugs 1999, 17:173-177.
69. Feldman E., Arlin Z., Ahmed T., Mittelman A., Puccio C., Chun H., et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992, 6:1189-1191.
70. Kantarjian H., Talpaz M., Smith T.L., Cortes J., Giles F.J., Rios M.B., et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J. Clin. Oncol. 2000, 18:3513-3521.
71. O'Brien S., Kantarjian H., Koller C., Feldman E., Beran M., Andreeff M., et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999, 93:4149-4153.
72. O'Brien S., Talpaz M., Cortes J., Shan J., Giles F.J., Faderl S., et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002, 94:2024-2032.
73. Zhu J., Ding B., Li Y. Long-term effect of interferon-alpha combined with homoharringtonine on chronic myelogenous leukemia in chronic phase. Leuke Lymph 2013, 54:1426-1429.
74. Marin D., Kaeda J.S., Andreasson C., Saunders S.M., Bua M., Olavarria E., et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005, 103:1850-1855.
75. O'Brien S., Giles F., Talpaz M., Cortes J., Rios M.B., Shan J., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003, 98:888-893.
76. Cortes J.E., Nicolini F.E., Wetzler M., Lipton J.H., Akard L., Craig A., et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymph, Myeloma Leuke 2013, 13:584-591.
77. Nicolini F.E., Khoury H.J., Akard L., Rea D., Kantarjian H., Baccarani M., et al. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 2013, 98:e78-e79.
78. Cortes J., Lipton J.H., Rea D., Digumarti R., Chuah C., Nanda N., et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012, 120:2573-2580.
79. Legros L., Hayette S., Nicolini F.E., Raynaud S., Chabane K., Magaud J.P., et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge. Leukemia 2007, 21:2204-2206.
80. Nicolini F.E., Chomel J.C., Roy L., Legros L., Chabane K., Ducastelle S., et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymph, Myeloma Leuke 2010, 10:394-399.
81. Coude M.M., Luycx O., Cariou M.E., Maarek O., Dombret H., Cayuela J.M., et al. Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation. Br. J. Haematol. 2012, 157:407-410.
82. Cortes J., Nicolini F.E., Wetzler M., Lipton J.H., Akard L., Craig A., et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin. Lymphoma Myeloma Leuk. 2013, 13:584-591.